Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
abandoned, accrual, AMD, ASU, Attenukine, Blue, cquisition, cu, Dasatinib, degeneration, Digihaler, ease, energy, EPS, estop, fluctuating, geopolitical, hryvna, inlieu, intense, Levothyroxine, Macrobid, macroeconomic, macular, mcg, nearest, Nitrofurantoin, ofthe, ompany, ophthalmology, osteoarthritic, Paclitaxel, pattern, paymentand, PEC, pershare, proportional, Ranivisio, Reddy, resubmitted, Shield, Sodium, Solicitor, Sprycel, spurred, statementsof, sum, supplier, Synthroid, theC, tightening, Vermont, volatility
Removed:
achieved, adequate, arm, Belrapzo, compare, consulting, core, discussing, distribute, dosing, efficacy, emerge, essential, evidence, FACT, functioning, inclusive, intention, leading, monthly, NaN, nominally, numerical, pack, physical, placebo, ranibizumab, recommendation, recruitment, reduced, redundancy, responded, responsibility, showed, significance, singled, statistical, uninterrupted, week
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view